SCHEMBL217793

SCHEMBL217793

[O]C(=O)c1c(F)c(F)c(F)c(F)c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
HTT P42858 3/20 0.40
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
MAPK1 P28482 1/20 0.37
GAA P10253 1/20 0.36
PKM P14618 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TSHR P16473 2/20 0.32
RECQL P46063 1/20 0.32
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
CA4 P22748 2/20 0.32
HDAC3 O15379 1/20 0.31
HDAC11 Q96DB2 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20853606 0.82 CES2 (0.32) CES2CES1HTT
SCHEMBL8175703 0.74 CES2 (0.68) CES2CES1HTTLMNATP53
SCHEMBL661258 0.74 CES2 (0.46) CES2CES1HTTLMNATP53
SCHEMBL4623333 0.73 CES2 (0.52) CES2CES1HTTLMNATP53
SCHEMBL317184 0.71 CES2 (0.43) CES2CES1HTTLMNATP53
SCHEMBL6448128 0.71 CES2 (0.43) CES2CES1HTTLMNATP53
SCHEMBL29449985 0.71 CES2 (0.43) CES2CES1HTTLMNATP53
SCHEMBL203915 0.71 CES2 (0.43) CES2CES1HTTLMNATP53
SCHEMBL336394 0.71 CES2 (0.43) CES2CES1HTTLMNATP53
SCHEMBL4962392 0.69 CES2 (0.42) CES2CES1HTTLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 538 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993754-B2 Iridium complex and light emitting material formed from same NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2015-03-31 US claimed
US-12012426-B2 Tetradentate diaminodiphosphine ligand and transition metal complex, and method for manufacturing same and application for same TAKASAGO INTERNATIONAL CORPORATION (JP) 2024-06-18 US disclosed
US-20240091228-A1 Uridine Phosphorylase Inhibitors to Prevent or Treat Drug-Induced Pulmonary Dysfunction TOSK, INC. 2024-03-21 US disclosed
CN-117597139-A Uridine phosphorylase inhibitors for preventing or treating drug-induced pulmonary dysfunction 托斯克公司 2024-02-23 CN disclosed
CN-117581124-A Resin film for polarizing plate, method for producing same, polarizing plate, and display device 柯尼卡美能达株式会社 2024-02-20 CN disclosed
EP-4301398-A1 URIDINE PHOSPHORYLASE INHIBITORS TO PREVENT OR TREAT DRUG-INDUCED PULMONARY DYSFUNCTION Tosk, Inc. (US) 2024-01-10 EP disclosed
US-20230405155-A1 NANOPARTICLE, PHOTOACOUSTIC CONTRAST AGENT, PHOTODYNAMIC THERAPY DRUG, AND PHOTOTHERMAL THERAPY DRUG SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-12-21 US disclosed
EP-4241846-A1 NANOPARTICLES, PHOTOACOUSTIC CONTRAST AGENT, PHOTODYNAMIC THERAPEUTIC AGENT, AND PHOTOTHERMAL THERAPEUTIC AGENT SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-09-13 EP disclosed
US-20230255971-A1 Uridine Phosphorylase (UPase) Inhibitors for Treatment of Liver Conditions TOSK, INC. 2023-08-17 US disclosed
US-20230219983-A1 TETRADENTATE DIAMINODIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX, AND METHOD FOR MANUFACTURING SAME AND APPLICATION FOR SAME TAKASAGO INTERNATIONAL CORPORATION (JP) 2023-07-13 US disclosed
EP-1117004-A2 Electron beam or x-ray negative-working resist composition FUJI PHOTO FILM CO., LTD. (JP) 2001-07-18 EP disclosed
EP-1109066-A1 Chemical amplification type negative-working resist composition for electron beams or x-rays FUJI PHOTO FILM CO., LTD. (JP) 2001-06-20 EP disclosed
US-6204390-B1 REACTING A AROMATIC AMIDE COMPOUND WITH A OXAZOLIDIN-2,4-DIONE COMPOUND KONICA CORPORATION (JP) 2001-03-20 US disclosed
EP-1076261-A1 Negative resist composition FUJI PHOTO FILM CO., LTD. (JP) 2001-02-14 EP disclosed
US-6027867-A HAVING IMPROVED YELLOW COUPLER MOIETY CAPABLE OF COUPLING REACTION WITH AN OXIDATION PRODUCT OF A COLOR DEVELOPING AGENT AND BEING BONDED THROUGH A TRIAZOLE TO AN A-THIOCARBOXYLIC ESTER GROUP; STORAGE STABILITY KONICA CORPORATION (JP) 2000-02-22 US disclosed
EP-0976740-A1 A synthesizing method for a 3-substituted-3-OXO-2-(2,4- Oxazolidinedion-3-YL)propionic acid amide compound KONICA CORPORATION (JP) 2000-02-02 EP disclosed
US-5556740-A DIFFUSION TRANSFER PROCESS FOR SUPPORT WITH MULTILAYER HYDROPHILIC BINDER WITH SILVER HALIDE AND DYE KONICA CORPORATION (JP) 1996-09-17 US disclosed
EP-0656562-A2 Diffusion transfer heat processable photosensitive material KONICA CORPORATION (JP) 1995-06-07 EP disclosed
US-5336593-A With pyrazolotriazole magenta couplers, for image durability, lightfastness, efficient color formation, color reproduction KONICA CORPORATION (JP) 1994-08-09 US disclosed
EP-0379174-A2 2,3-Dihydro-3,3-dimethyl-5-trifluoromethanesulfonyloxybenzofurans, process for producing them and herbicides containing them MITSUI TOATSU CHEMICALS, Inc. (JP) 1990-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230405155-A1 NANOPARTICLE, PHOTOACOUSTIC CONTRAST AGENT, PHOTODYNAMIC THERAPY DRUG, AND PHOTOTHERMAL THERAPY DRUG CRY2, RB1, NR2E3 CES2 1904/4885CES1 3223/4885HTT 1895/4885
US-20230219983-A1 TETRADENTATE DIAMINODIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX, AND METHOD FOR MANUFACTURING SAME AND APPLICATION FOR SAME ADH4, ADH5, PF4 CES2 2676/4885CES1 3668/4885HTT 652/4885
US-12012426-B2 Tetradentate diaminodiphosphine ligand and transition metal complex, and method for manufacturing same and application for same ADH4, ADH5, PF4 CES2 2676/4885CES1 3668/4885HTT 652/4885
US-20230255971-A1 Uridine Phosphorylase (UPase) Inhibitors for Treatment of Liver Conditions UMPS, UPP1, PNP CES2 342/4885CES1 50/4885HTT 2944/4885
US-20240091228-A1 Uridine Phosphorylase Inhibitors to Prevent or Treat Drug-Induced Pulmonary Dysfunction UMPS, UPP1, PNP CES2 938/4885CES1 456/4885HTT 4397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.